CureMint Welcomes John Klavon as VP of Sales and Business Development

Share This Post

Key Highlights

  • CureMint names John Klavon as Vice President of Sales and Business Development.
  • Klavon brings over 32 years of dental and B2B sector experience.
  • Led procurement at Frontline Dental, achieving $2.8 million in savings using CureMint’s platform.
  • Expertise in unifying Procurement and A/P workflows to drive efficiency and growth.

Source: Business Wire

Notable Quotes

  • “John recognized that today’s modern dental organizations need more than a procurement solution. They need an integrated Procure-to-Pay solution.” — Tyson Nargassans, CEO at CureMint
  • “I’m excited to join CureMint and look forward to leveraging my experience in the dental industry to contribute to CureMint’s vision and long-term success.” — John Klavon, VP of Sales and Business Development at CureMint

SoHC's Take

CureMint’s appointment of John Klavon marks a pivotal moment for the company, aligning with its mission to continue expanding its foothold in the dental sector. Klavon’s extensive leadership experience and firsthand success with CureMint’s platform at Frontline Dental suggest he is well-positioned to drive both sales and innovation. His deep understanding of dental organizations’ unique challenges, combined with his strategic mindset, will undoubtedly help CureMint further solidify its position as a leader in Procure-to-Pay solutions.

Heading

Key Highlights CalmWave closes a $5.25M financing round led by Third Prime with contributions from Catalyst by Wellstar, Silver Circle, and ...
/
Key Highlights Alice Koehler appointed Managing Director of OMRON Healthcare North America. Koehler brings 25+ years of global experience in ...
/
Key Highlights Koda Health introduces Kidney Action Planning to support Chronic Kidney Disease (CKD) management with cutting-edge tools. Features include gamified patient ...
/
Key Highlights Northwell Health’s Aging Revolution Summit will take place virtually and in-person in NYC on December 3, 2024. Key themes: Therapeutics, ...
/
Key Highlights $5M Series A funding led by Empactful Capital to fuel growth and innovation. Investment will support product development, strategic accounts, and new market ...
/
Key Highlights New Lantern raises $19M Series A funding, led by Benchmark, totaling $23M raised to date. Platform automates 25% of ...
/

More To Explore

Total
0
Share